Stage progression of small hepatocellular carcinoma after radical therapy: Comparisons of radiofrequency ablation and surgery using the Markov model

Liver International

Volumn 31, Issue 5, 2011, Pages 692-699

  Ikeda, Kenji ^a,b   Kobayashi, Masahiro ^a,b   Kawamura, Yusuke ^a,b   Imai, Norihiro ^a,b   Seko, Yuya ^a,b   Hirakawa, Miharu ^a,b   Hosaka, Tetsuya ^a,b   Sezaki, Hitomi ^a,b   Akuta, Norio ^a,b   Saitoh, Satoshi ^a,b   Suzuki, Fumitaka ^a,b   Suzuki, Yoshiyuki ^a,b   Arase, Yasuji ^a,b   Kumada, Hiromitsu ^a,b  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

Author keywords

Hepatocellular carcinoma; Markov model; Radiofrequency ablation; Recurrence; Surgery; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; FEMALE; HAZARD RATIO; HIDDEN MARKOV MODEL; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; RADICAL RESECTION; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HEPATECTOMY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953313207     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02480.x     Document Type: Article

References (22)

1. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16.
2. Ikai I, Yuji I, Okita M, et al. Report of the 15th follow-up survey of primary liver cancer. The liver cancer study group of Japan. Hepatol Res 2004; 28: 21-9.
3. Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer. The liver cancer study group of Japan. Hepatol Res 2005; 32: 163-72.
4. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ III. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005; 129: 486-93.
5. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158-66.
6. Ikeda K, Arase Y, Kobayashi M, et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 882 patients with viral cirrhosis. J Gastroenterol 2003; 38: 865-76.
7. Ueno S, Aoki D, Maeda T, et al. Preoperative assessment of multicentric occurrence in synchronous small and multiple hepatocellular carcinoma based on image-patterns and histological grading of non-cancerous region. Hepatol Res 2004; 29: 24-30.
8. Wang J, Li Q, Sun Y, et al. Clinicopathologic features between multicentric occurrence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol 2009; 18: 25-30.
9. Livraghi T, Meloni F, DiStasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82-9.
10. Ikeda K, Kobayashi M, Saitoh S, et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter. Hepatol Res 2005; 33: 241-9.
11. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8.
12. Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008; 12: 192-8.
13. Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB 2005; 7: 214-21.
14. Chen MS, Li JQ, Zheng Y, et al. A Prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8.
15. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
16. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
17. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-58.
18. Silverstein MD, Albert DA, Hadler NM, Ropes MW. Prognosis of SLE: comparison of Markov model to life table analysis. J Clin Epidemiol 1988; 41: 623-33.
19. IBM SPSS Inc. IBM SPSS for Windows version 18.0 Manual. Armonk, NY, USA: SPSS Japan Inc., an IBM company, 2009.
20. Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhosis individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg 2006; 198: 396-406.
21. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010; 51: 1284-90.
22. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009; 249: 20-5.